TGF beta 1/TGFB1 LAP Protein, Human (249a.a, HEK293)

The Latency-associated peptide (LAP) of Transforming growth factor beta-1 (TGF-beta-1) proprotein is a crucial precursor, forming a complex with TGF-beta-1. LAP maintains the latent state of TGF-beta-1 during extracellular matrix storage, ensuring controlled activation. Interactions with 'milieu molecules' like LTBP1, LRRC32/GARP, and LRRC33/NRROS intricately regulate TGF-beta-1 activation. LRRC33/NRROS influences activation in macrophages and microglia, while LRRC32/GARP controls activation on activated regulatory T-cells. Interactions with integrins induce conformational changes in LAP, releasing active TGF-beta-1. LAP orchestrates controlled TGF-beta-1 activation in diverse physiological contexts. TGF beta 1/TGFB1 LAP Protein, Human (249a.a, HEK293) is the recombinant human-derived TGF beta 1/TGFB1 LAP protein, expressed by HEK293 , with tag free. and C33S mutation. The total length of TGF beta 1/TGFB1 LAP Protein, Human (249a.a, HEK293) is 249 a.a., with molecular weight of 20-45 kDa.

The Latency-associated peptide (LAP) of Transforming growth factor beta-1 (TGF-beta-1) proprotein serves as a crucial precursor, forming a complex with TGF-beta-1 to constitute the regulatory and active subunits, respectively. LAP plays a pivotal role in maintaining the latent state of TGF-beta-1 during extracellular matrix storage, ensuring controlled activation upon specific triggers. Interactions with key 'milieu molecules' such as LTBP1, LRRC32/GARP, and LRRC33/NRROS intricately regulate TGF-beta-1 activation. LRRC33/NRROS influences TGF-beta-1 activation in macrophages and microglia, while LRRC32/GARP controls activation on activated regulatory T-cells (Tregs). Furthermore, interactions with integrins (ITGAV:ITGB6 or ITGAV:ITGB8) induce conformational changes in LAP, leading to the release of active TGF-beta-1. This dynamic interplay highlights LAP's crucial role in orchestrating the controlled activation of TGF-beta-1 in various physiological contexts.

1.Measured by its ability to inhibit TGF-β1 activity on HT-2 mouse T cells. The ED₅₀ this effect is 22.78 ng/mL in the presence of 1 ng/mL TGF-β1, corresponding to a specific activity is 4.39×10⁴units/mg.
2.Measured by its ability to inhibit the IL-4-dependent proliferation of HT‑2 mouse T cells.The ED₅₀ for this effect is 0.01185 ng/ml, corresponding to a specific activity is 8.43×10⁴ units/mg.

• 
  Measured by its ability to inhibit TGF-β1 activity on HT‑2 mouse T cells. The ED₅₀ this effect is 22.78 ng/mL in the presence of 1 ng/mL TGF-β1, corresponding to a specific activity is 4.39×10⁴ units/mg.

Human

HEK293

Tag Free

P01137 (L30-R278, C33S)

7040  [NCBI]

LSTSKTIDMELVKRKRIEAIRGQILSKLRLASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRR

20-45 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in PBS, pH 7.4. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.